Match each clinical presentation of infective endocarditis or severe bacteremia to its most appropriate targeted antimicrobial regimen.
- Prosthetic aortic valve (placed 3 months ago) endocarditis growing methicillin-resistant Staphylococcus epidermidis (MRSE)Intravenous vancomycin, rifampin, and gentamicin
- Native mitral valve endocarditis growing Enterococcus faecalis in a patient with stage 3 chronic kidney diseaseIntravenous ampicillin and ceftriaxone
- Native tricuspid valve endocarditis growing methicillin-susceptible Staphylococcus aureus (MSSA) currently on empiric vancomycinIntravenous cefazolin
- Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia with a rapidly rising serum creatinine on day 4 of vancomycin therapyIntravenous daptomycin
Cevap
Prosthetic valve MRSE matches with Vancomycin/Rifampin/Gentamicin. E. faecalis with CKD matches with Ampicillin/Ceftriaxone. MSSA matches with Cefazolin. MRSA with nephrotoxicity matches with Daptomycin.
Each correct pairing aligns with infectious disease guidelines: staphylococcal prosthetic valves require rifampin and gentamicin adjuncts; MSSA strictly requires beta-lactam de-escalation; enterococcal endocarditis with renal impairment requires aminoglycoside-sparing dual beta-lactams; and vancomycin-induced nephrotoxicity necessitates a switch to daptomycin.
Adım Adım Çözüm
Anahtar Kavram
Targeted antimicrobial therapy for bacteremia and endocarditis requires adjustment based on pathogen susceptibility (e.g., MRSA vs. MSSA), infection site (prosthetic biofilm vs. native valve), and patient-specific toxicities (nephrotoxicity).